Dutch specialty chemicals maker DSM in May struck back-to-back deals to sell its engineering plastics division and to combine with Firmenich to focus on the fast-growing food, fragrance and health products markets.
Family-controlled Firmenich said its full-year earnings before interest, tax, depreciation and amortisation (EBITDA), adjusted for one-offs, reached a record high of 905 million Swiss francs ($946 million) for the full year ended June 30.
It said in a statement its earnings were also bolstered by 20% growth in sugar replacement products and a business with makers of plant-based proteins that more than doubled.
Shaky supply chains prompted Firmenich to keep higher stocks of raw materials, resulting in a 5.9% drop in adjusted free cash flow, which it said was also hit by cost inflation.
DSM, whose leadership team will head the combined group, this week reiterated its full-year profit guidance for its core business areas health, nutrition and bioscience.
While DSM's adjusted EBITDA is still projected to grow by a "high-single digit" percentage, Firmenich, said on Friday it would not provide short-term earnings guidance.
"The two companies are getting into this merger from a position of strength and I think the record year that we have announced is another proof that this is the case," Firmenich CEO Gilbert Ghostine told Reuters.
Under the merger, which is expected to be wrapped up during the first half of next year, DSM shareholders will take a 65.5% stake, while the family behind unlisted Firmenich will get 34.5%plus 3.5 billion euros ($3.58 billion) in cash.
($1 = 0.9564 Swiss francs)
($1 = 0.9773 euros)
(Reporting by Ludwig Burger; Editing by Rachel More, Rashmi Aich and Alexander Smith)
By Ludwig Burger